nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A1—prostate cancer	0.359	1	CbGaD
Amantadine—SLC22A2—Estradiol—prostate cancer	0.0496	0.183	CbGbCtD
Amantadine—SLC22A1—Estradiol—prostate cancer	0.0431	0.159	CbGbCtD
Amantadine—ABCB1—Estramustine—prostate cancer	0.0357	0.132	CbGbCtD
Amantadine—ABCB1—Cabazitaxel—prostate cancer	0.0235	0.0868	CbGbCtD
Amantadine—ABCB1—Estrone—prostate cancer	0.023	0.0848	CbGbCtD
Amantadine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0205	0.0756	CbGbCtD
Amantadine—ABCB1—Conjugated Estrogens—prostate cancer	0.0151	0.0555	CbGbCtD
Amantadine—ABCB1—Mitoxantrone—prostate cancer	0.0137	0.0504	CbGbCtD
Amantadine—ABCB1—Estradiol—prostate cancer	0.0132	0.0487	CbGbCtD
Amantadine—ABCB1—Prednisone—prostate cancer	0.0114	0.0419	CbGbCtD
Amantadine—ABCB1—Etoposide—prostate cancer	0.00863	0.0318	CbGbCtD
Amantadine—ABCB1—Docetaxel—prostate cancer	0.00789	0.0291	CbGbCtD
Amantadine—ABCB1—Doxorubicin—prostate cancer	0.00589	0.0217	CbGbCtD
Amantadine—GRIN2D—prostate gland—prostate cancer	0.00329	0.112	CbGeAlD
Amantadine—GRIN3B—testis—prostate cancer	0.00325	0.11	CbGeAlD
Amantadine—GRIN2C—testis—prostate cancer	0.00156	0.053	CbGeAlD
Amantadine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00156	1	CbGdCrCtD
Amantadine—DDC—renal system—prostate cancer	0.00156	0.0529	CbGeAlD
Amantadine—GRIN2D—testis—prostate cancer	0.00145	0.0492	CbGeAlD
Amantadine—GRIN3A—testis—prostate cancer	0.00136	0.0463	CbGeAlD
Amantadine—SLC22A2—renal system—prostate cancer	0.00128	0.0436	CbGeAlD
Amantadine—SIGMAR1—prostate gland—prostate cancer	0.00123	0.0417	CbGeAlD
Amantadine—MAOB—prostate gland—prostate cancer	0.00118	0.0399	CbGeAlD
Amantadine—GRIN2A—testis—prostate cancer	0.00108	0.0366	CbGeAlD
Amantadine—SIGMAR1—seminal vesicle—prostate cancer	0.00104	0.0353	CbGeAlD
Amantadine—DDC—testis—prostate cancer	0.00101	0.0342	CbGeAlD
Amantadine—MAOB—seminal vesicle—prostate cancer	0.000995	0.0338	CbGeAlD
Amantadine—SLC22A1—renal system—prostate cancer	0.000907	0.0308	CbGeAlD
Amantadine—SIGMAR1—urethra—prostate cancer	0.000823	0.0279	CbGeAlD
Amantadine—MAOB—renal system—prostate cancer	0.000802	0.0272	CbGeAlD
Amantadine—MAOB—urethra—prostate cancer	0.000788	0.0267	CbGeAlD
Amantadine—DDC—lymph node—prostate cancer	0.00073	0.0248	CbGeAlD
Amantadine—SIGMAR1—bone marrow—prostate cancer	0.000634	0.0215	CbGeAlD
Amantadine—SIGMAR1—testis—prostate cancer	0.000542	0.0184	CbGeAlD
Amantadine—MAOB—testis—prostate cancer	0.000518	0.0176	CbGeAlD
Amantadine—DRD2—testis—prostate cancer	0.000437	0.0148	CbGeAlD
Amantadine—ABCB1—prostate gland—prostate cancer	0.000429	0.0146	CbGeAlD
Amantadine—SIGMAR1—lymph node—prostate cancer	0.000393	0.0133	CbGeAlD
Amantadine—MAOB—lymph node—prostate cancer	0.000376	0.0127	CbGeAlD
Amantadine—ABCB1—seminal vesicle—prostate cancer	0.000363	0.0123	CbGeAlD
Amantadine—ABCB1—epithelium—prostate cancer	0.000315	0.0107	CbGeAlD
Amantadine—ABCB1—renal system—prostate cancer	0.000293	0.00993	CbGeAlD
Amantadine—ABCB1—urethra—prostate cancer	0.000287	0.00975	CbGeAlD
Amantadine—ABCB1—bone marrow—prostate cancer	0.000221	0.0075	CbGeAlD
Amantadine—ABCB1—testis—prostate cancer	0.000189	0.00642	CbGeAlD
Amantadine—ABCB1—lymph node—prostate cancer	0.000137	0.00465	CbGeAlD
Amantadine—Dysphagia—Doxorubicin—prostate cancer	9.71e-05	0.000489	CcSEcCtD
Amantadine—Leukopenia—Docetaxel—prostate cancer	9.7e-05	0.000488	CcSEcCtD
Amantadine—Arrhythmia—Prednisone—prostate cancer	9.59e-05	0.000483	CcSEcCtD
Amantadine—Palpitations—Docetaxel—prostate cancer	9.58e-05	0.000482	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—prostate cancer	9.58e-05	0.000482	CcSEcCtD
Amantadine—Paraesthesia—Etoposide—prostate cancer	9.56e-05	0.000481	CcSEcCtD
Amantadine—Dyspnoea—Etoposide—prostate cancer	9.49e-05	0.000478	CcSEcCtD
Amantadine—Alopecia—Prednisone—prostate cancer	9.49e-05	0.000478	CcSEcCtD
Amantadine—Somnolence—Etoposide—prostate cancer	9.46e-05	0.000476	CcSEcCtD
Amantadine—Hypersensitivity—Mitoxantrone—prostate cancer	9.43e-05	0.000474	CcSEcCtD
Amantadine—Mental disorder—Prednisone—prostate cancer	9.41e-05	0.000473	CcSEcCtD
Amantadine—Diarrhoea—Estradiol—prostate cancer	9.4e-05	0.000473	CcSEcCtD
Amantadine—Leukopenia—Capecitabine—prostate cancer	9.39e-05	0.000473	CcSEcCtD
Amantadine—Convulsion—Docetaxel—prostate cancer	9.39e-05	0.000473	CcSEcCtD
Amantadine—Hypertension—Docetaxel—prostate cancer	9.36e-05	0.000471	CcSEcCtD
Amantadine—Malnutrition—Prednisone—prostate cancer	9.35e-05	0.00047	CcSEcCtD
Amantadine—Palpitations—Capecitabine—prostate cancer	9.27e-05	0.000467	CcSEcCtD
Amantadine—Decreased appetite—Etoposide—prostate cancer	9.25e-05	0.000466	CcSEcCtD
Amantadine—Gastrointestinal disorder—Etoposide—prostate cancer	9.19e-05	0.000462	CcSEcCtD
Amantadine—Asthenia—Mitoxantrone—prostate cancer	9.18e-05	0.000462	CcSEcCtD
Amantadine—Fatigue—Etoposide—prostate cancer	9.18e-05	0.000462	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	9.16e-05	0.000461	CcSEcCtD
Amantadine—Constipation—Etoposide—prostate cancer	9.1e-05	0.000458	CcSEcCtD
Amantadine—Dizziness—Estradiol—prostate cancer	9.08e-05	0.000457	CcSEcCtD
Amantadine—Neutropenia—Doxorubicin—prostate cancer	9.08e-05	0.000457	CcSEcCtD
Amantadine—Hypertension—Capecitabine—prostate cancer	9.06e-05	0.000456	CcSEcCtD
Amantadine—Dry mouth—Docetaxel—prostate cancer	9.03e-05	0.000454	CcSEcCtD
Amantadine—Confusional state—Docetaxel—prostate cancer	8.92e-05	0.000449	CcSEcCtD
Amantadine—Anxiety—Capecitabine—prostate cancer	8.9e-05	0.000448	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	8.87e-05	0.000447	CcSEcCtD
Amantadine—Photosensitivity reaction—Doxorubicin—prostate cancer	8.86e-05	0.000446	CcSEcCtD
Amantadine—Oedema—Docetaxel—prostate cancer	8.85e-05	0.000445	CcSEcCtD
Amantadine—Anaphylactic shock—Docetaxel—prostate cancer	8.85e-05	0.000445	CcSEcCtD
Amantadine—Vision blurred—Prednisone—prostate cancer	8.81e-05	0.000443	CcSEcCtD
Amantadine—Feeling abnormal—Etoposide—prostate cancer	8.77e-05	0.000441	CcSEcCtD
Amantadine—Diarrhoea—Mitoxantrone—prostate cancer	8.76e-05	0.000441	CcSEcCtD
Amantadine—Dry mouth—Capecitabine—prostate cancer	8.74e-05	0.00044	CcSEcCtD
Amantadine—Vomiting—Estradiol—prostate cancer	8.73e-05	0.000439	CcSEcCtD
Amantadine—Agranulocytosis—Epirubicin—prostate cancer	8.73e-05	0.000439	CcSEcCtD
Amantadine—Nervous system disorder—Docetaxel—prostate cancer	8.68e-05	0.000437	CcSEcCtD
Amantadine—Rash—Estradiol—prostate cancer	8.66e-05	0.000436	CcSEcCtD
Amantadine—Dermatitis—Estradiol—prostate cancer	8.65e-05	0.000435	CcSEcCtD
Amantadine—Confusional state—Capecitabine—prostate cancer	8.64e-05	0.000435	CcSEcCtD
Amantadine—Tachycardia—Docetaxel—prostate cancer	8.63e-05	0.000434	CcSEcCtD
Amantadine—Headache—Estradiol—prostate cancer	8.6e-05	0.000433	CcSEcCtD
Amantadine—Skin disorder—Docetaxel—prostate cancer	8.59e-05	0.000432	CcSEcCtD
Amantadine—Agitation—Prednisone—prostate cancer	8.59e-05	0.000432	CcSEcCtD
Amantadine—Oedema—Capecitabine—prostate cancer	8.57e-05	0.000431	CcSEcCtD
Amantadine—Anorexia—Docetaxel—prostate cancer	8.43e-05	0.000424	CcSEcCtD
Amantadine—Body temperature increased—Etoposide—prostate cancer	8.42e-05	0.000423	CcSEcCtD
Amantadine—Nervous system disorder—Capecitabine—prostate cancer	8.4e-05	0.000423	CcSEcCtD
Amantadine—Tachycardia—Capecitabine—prostate cancer	8.36e-05	0.000421	CcSEcCtD
Amantadine—Skin disorder—Capecitabine—prostate cancer	8.32e-05	0.000419	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—prostate cancer	8.29e-05	0.000417	CcSEcCtD
Amantadine—Hyperhidrosis—Capecitabine—prostate cancer	8.28e-05	0.000417	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—prostate cancer	8.27e-05	0.000416	CcSEcCtD
Amantadine—Hypotension—Docetaxel—prostate cancer	8.27e-05	0.000416	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—prostate cancer	8.23e-05	0.000414	CcSEcCtD
Amantadine—Anorexia—Capecitabine—prostate cancer	8.16e-05	0.000411	CcSEcCtD
Amantadine—Nausea—Estradiol—prostate cancer	8.16e-05	0.000411	CcSEcCtD
Amantadine—Vomiting—Mitoxantrone—prostate cancer	8.14e-05	0.000409	CcSEcCtD
Amantadine—Convulsion—Prednisone—prostate cancer	8.1e-05	0.000408	CcSEcCtD
Amantadine—Visual impairment—Epirubicin—prostate cancer	8.09e-05	0.000407	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—prostate cancer	8.08e-05	0.000407	CcSEcCtD
Amantadine—Hypertension—Prednisone—prostate cancer	8.07e-05	0.000406	CcSEcCtD
Amantadine—Rash—Mitoxantrone—prostate cancer	8.07e-05	0.000406	CcSEcCtD
Amantadine—Dermatitis—Mitoxantrone—prostate cancer	8.06e-05	0.000406	CcSEcCtD
Amantadine—Headache—Mitoxantrone—prostate cancer	8.02e-05	0.000403	CcSEcCtD
Amantadine—Hypotension—Capecitabine—prostate cancer	8e-05	0.000403	CcSEcCtD
Amantadine—Insomnia—Docetaxel—prostate cancer	8e-05	0.000403	CcSEcCtD
Amantadine—Paraesthesia—Docetaxel—prostate cancer	7.94e-05	0.0004	CcSEcCtD
Amantadine—Anxiety—Prednisone—prostate cancer	7.93e-05	0.000399	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	7.9e-05	0.000398	CcSEcCtD
Amantadine—Dyspnoea—Docetaxel—prostate cancer	7.89e-05	0.000397	CcSEcCtD
Amantadine—Somnolence—Docetaxel—prostate cancer	7.86e-05	0.000396	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—prostate cancer	7.85e-05	0.000395	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—prostate cancer	7.84e-05	0.000395	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—prostate cancer	7.79e-05	0.000392	CcSEcCtD
Amantadine—Dyspepsia—Docetaxel—prostate cancer	7.79e-05	0.000392	CcSEcCtD
Amantadine—Insomnia—Capecitabine—prostate cancer	7.75e-05	0.00039	CcSEcCtD
Amantadine—Paraesthesia—Capecitabine—prostate cancer	7.69e-05	0.000387	CcSEcCtD
Amantadine—Decreased appetite—Docetaxel—prostate cancer	7.69e-05	0.000387	CcSEcCtD
Amantadine—Urinary tract disorder—Doxorubicin—prostate cancer	7.67e-05	0.000386	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—prostate cancer	7.66e-05	0.000385	CcSEcCtD
Amantadine—Gastrointestinal disorder—Docetaxel—prostate cancer	7.64e-05	0.000384	CcSEcCtD
Amantadine—Asthenia—Etoposide—prostate cancer	7.64e-05	0.000384	CcSEcCtD
Amantadine—Dyspnoea—Capecitabine—prostate cancer	7.64e-05	0.000384	CcSEcCtD
Amantadine—Anaphylactic shock—Prednisone—prostate cancer	7.63e-05	0.000384	CcSEcCtD
Amantadine—Oedema—Prednisone—prostate cancer	7.63e-05	0.000384	CcSEcCtD
Amantadine—Fatigue—Docetaxel—prostate cancer	7.63e-05	0.000384	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—prostate cancer	7.62e-05	0.000383	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—prostate cancer	7.62e-05	0.000383	CcSEcCtD
Amantadine—Nausea—Mitoxantrone—prostate cancer	7.6e-05	0.000383	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—prostate cancer	7.57e-05	0.000381	CcSEcCtD
Amantadine—Constipation—Docetaxel—prostate cancer	7.57e-05	0.000381	CcSEcCtD
Amantadine—Dyspepsia—Capecitabine—prostate cancer	7.54e-05	0.000379	CcSEcCtD
Amantadine—Pruritus—Etoposide—prostate cancer	7.53e-05	0.000379	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—prostate cancer	7.5e-05	0.000378	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—prostate cancer	7.49e-05	0.000377	CcSEcCtD
Amantadine—Nervous system disorder—Prednisone—prostate cancer	7.48e-05	0.000377	CcSEcCtD
Amantadine—Tachycardia—Prednisone—prostate cancer	7.45e-05	0.000375	CcSEcCtD
Amantadine—Decreased appetite—Capecitabine—prostate cancer	7.45e-05	0.000375	CcSEcCtD
Amantadine—Alopecia—Epirubicin—prostate cancer	7.42e-05	0.000373	CcSEcCtD
Amantadine—Skin disorder—Prednisone—prostate cancer	7.41e-05	0.000373	CcSEcCtD
Amantadine—Gastrointestinal disorder—Capecitabine—prostate cancer	7.39e-05	0.000372	CcSEcCtD
Amantadine—Fatigue—Capecitabine—prostate cancer	7.38e-05	0.000372	CcSEcCtD
Amantadine—Hyperhidrosis—Prednisone—prostate cancer	7.38e-05	0.000371	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—prostate cancer	7.36e-05	0.00037	CcSEcCtD
Amantadine—Constipation—Capecitabine—prostate cancer	7.32e-05	0.000369	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—prostate cancer	7.31e-05	0.000368	CcSEcCtD
Amantadine—Feeling abnormal—Docetaxel—prostate cancer	7.29e-05	0.000367	CcSEcCtD
Amantadine—Diarrhoea—Etoposide—prostate cancer	7.28e-05	0.000367	CcSEcCtD
Amantadine—Anorexia—Prednisone—prostate cancer	7.27e-05	0.000366	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—prostate cancer	7.26e-05	0.000365	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—prostate cancer	7.21e-05	0.000363	CcSEcCtD
Amantadine—Tension—Epirubicin—prostate cancer	7.17e-05	0.000361	CcSEcCtD
Amantadine—Nervousness—Epirubicin—prostate cancer	7.1e-05	0.000357	CcSEcCtD
Amantadine—Feeling abnormal—Capecitabine—prostate cancer	7.06e-05	0.000355	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—prostate cancer	7.05e-05	0.000355	CcSEcCtD
Amantadine—Dizziness—Etoposide—prostate cancer	7.04e-05	0.000354	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—prostate cancer	7e-05	0.000352	CcSEcCtD
Amantadine—Body temperature increased—Docetaxel—prostate cancer	6.99e-05	0.000352	CcSEcCtD
Amantadine—Arrhythmia—Doxorubicin—prostate cancer	6.94e-05	0.000349	CcSEcCtD
Amantadine—Insomnia—Prednisone—prostate cancer	6.9e-05	0.000347	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—prostate cancer	6.89e-05	0.000347	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—prostate cancer	6.87e-05	0.000346	CcSEcCtD
Amantadine—Paraesthesia—Prednisone—prostate cancer	6.85e-05	0.000345	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—prostate cancer	6.81e-05	0.000343	CcSEcCtD
Amantadine—Body temperature increased—Capecitabine—prostate cancer	6.77e-05	0.000341	CcSEcCtD
Amantadine—Vomiting—Etoposide—prostate cancer	6.77e-05	0.000341	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—prostate cancer	6.77e-05	0.00034	CcSEcCtD
Amantadine—Agitation—Epirubicin—prostate cancer	6.72e-05	0.000338	CcSEcCtD
Amantadine—Dyspepsia—Prednisone—prostate cancer	6.72e-05	0.000338	CcSEcCtD
Amantadine—Rash—Etoposide—prostate cancer	6.71e-05	0.000338	CcSEcCtD
Amantadine—Dermatitis—Etoposide—prostate cancer	6.71e-05	0.000337	CcSEcCtD
Amantadine—Headache—Etoposide—prostate cancer	6.67e-05	0.000336	CcSEcCtD
Amantadine—Tension—Doxorubicin—prostate cancer	6.64e-05	0.000334	CcSEcCtD
Amantadine—Decreased appetite—Prednisone—prostate cancer	6.63e-05	0.000334	CcSEcCtD
Amantadine—Fatigue—Prednisone—prostate cancer	6.58e-05	0.000331	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—prostate cancer	6.57e-05	0.000331	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—prostate cancer	6.54e-05	0.000329	CcSEcCtD
Amantadine—Constipation—Prednisone—prostate cancer	6.52e-05	0.000328	CcSEcCtD
Amantadine—Hypersensitivity—Docetaxel—prostate cancer	6.52e-05	0.000328	CcSEcCtD
Amantadine—Palpitations—Epirubicin—prostate cancer	6.46e-05	0.000325	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—prostate cancer	6.38e-05	0.000321	CcSEcCtD
Amantadine—Asthenia—Docetaxel—prostate cancer	6.35e-05	0.000319	CcSEcCtD
Amantadine—Convulsion—Epirubicin—prostate cancer	6.33e-05	0.000319	CcSEcCtD
Amantadine—Nausea—Etoposide—prostate cancer	6.32e-05	0.000318	CcSEcCtD
Amantadine—Hypertension—Epirubicin—prostate cancer	6.31e-05	0.000318	CcSEcCtD
Amantadine—Hypersensitivity—Capecitabine—prostate cancer	6.31e-05	0.000318	CcSEcCtD
Amantadine—Feeling abnormal—Prednisone—prostate cancer	6.29e-05	0.000316	CcSEcCtD
Amantadine—Pruritus—Docetaxel—prostate cancer	6.26e-05	0.000315	CcSEcCtD
Amantadine—Agitation—Doxorubicin—prostate cancer	6.22e-05	0.000313	CcSEcCtD
Amantadine—Anxiety—Epirubicin—prostate cancer	6.2e-05	0.000312	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.18e-05	0.000311	CcSEcCtD
Amantadine—Asthenia—Capecitabine—prostate cancer	6.15e-05	0.000309	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—prostate cancer	6.09e-05	0.000306	CcSEcCtD
Amantadine—Pruritus—Capecitabine—prostate cancer	6.06e-05	0.000305	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—prostate cancer	6.06e-05	0.000305	CcSEcCtD
Amantadine—Diarrhoea—Docetaxel—prostate cancer	6.05e-05	0.000305	CcSEcCtD
Amantadine—Body temperature increased—Prednisone—prostate cancer	6.03e-05	0.000304	CcSEcCtD
Amantadine—Confusional state—Epirubicin—prostate cancer	6.02e-05	0.000303	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—prostate cancer	5.98e-05	0.000301	CcSEcCtD
Amantadine—Oedema—Epirubicin—prostate cancer	5.97e-05	0.0003	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—prostate cancer	5.97e-05	0.0003	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—prostate cancer	5.86e-05	0.000295	CcSEcCtD
Amantadine—Diarrhoea—Capecitabine—prostate cancer	5.86e-05	0.000295	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—prostate cancer	5.85e-05	0.000294	CcSEcCtD
Amantadine—Dizziness—Docetaxel—prostate cancer	5.85e-05	0.000294	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—prostate cancer	5.84e-05	0.000294	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—prostate cancer	5.82e-05	0.000293	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—prostate cancer	5.8e-05	0.000292	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—prostate cancer	5.77e-05	0.00029	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—prostate cancer	5.74e-05	0.000289	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.72e-05	0.000288	CcSEcCtD
Amantadine—Anorexia—Epirubicin—prostate cancer	5.69e-05	0.000286	CcSEcCtD
Amantadine—Dizziness—Capecitabine—prostate cancer	5.66e-05	0.000285	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—prostate cancer	5.63e-05	0.000283	CcSEcCtD
Amantadine—Vomiting—Docetaxel—prostate cancer	5.62e-05	0.000283	CcSEcCtD
Amantadine—Hypersensitivity—Prednisone—prostate cancer	5.62e-05	0.000283	CcSEcCtD
Amantadine—Rash—Docetaxel—prostate cancer	5.58e-05	0.000281	CcSEcCtD
Amantadine—Hypotension—Epirubicin—prostate cancer	5.58e-05	0.000281	CcSEcCtD
Amantadine—Dermatitis—Docetaxel—prostate cancer	5.57e-05	0.00028	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—prostate cancer	5.57e-05	0.00028	CcSEcCtD
Amantadine—Headache—Docetaxel—prostate cancer	5.54e-05	0.000279	CcSEcCtD
Amantadine—Oedema—Doxorubicin—prostate cancer	5.52e-05	0.000278	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—prostate cancer	5.52e-05	0.000278	CcSEcCtD
Amantadine—Asthenia—Prednisone—prostate cancer	5.47e-05	0.000275	CcSEcCtD
Amantadine—Vomiting—Capecitabine—prostate cancer	5.45e-05	0.000274	CcSEcCtD
Amantadine—Nervous system disorder—Doxorubicin—prostate cancer	5.41e-05	0.000272	CcSEcCtD
Amantadine—Rash—Capecitabine—prostate cancer	5.4e-05	0.000272	CcSEcCtD
Amantadine—Pruritus—Prednisone—prostate cancer	5.4e-05	0.000272	CcSEcCtD
Amantadine—Insomnia—Epirubicin—prostate cancer	5.4e-05	0.000272	CcSEcCtD
Amantadine—Dermatitis—Capecitabine—prostate cancer	5.4e-05	0.000272	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—prostate cancer	5.39e-05	0.000271	CcSEcCtD
Amantadine—Headache—Capecitabine—prostate cancer	5.37e-05	0.00027	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—prostate cancer	5.36e-05	0.00027	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—prostate cancer	5.36e-05	0.00027	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—prostate cancer	5.34e-05	0.000269	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—prostate cancer	5.32e-05	0.000268	CcSEcCtD
Amantadine—Somnolence—Epirubicin—prostate cancer	5.3e-05	0.000267	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—prostate cancer	5.26e-05	0.000265	CcSEcCtD
Amantadine—Nausea—Docetaxel—prostate cancer	5.25e-05	0.000264	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—prostate cancer	5.25e-05	0.000264	CcSEcCtD
Amantadine—Diarrhoea—Prednisone—prostate cancer	5.22e-05	0.000263	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—prostate cancer	5.19e-05	0.000261	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—prostate cancer	5.16e-05	0.00026	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—prostate cancer	5.15e-05	0.000259	CcSEcCtD
Amantadine—Fatigue—Epirubicin—prostate cancer	5.14e-05	0.000259	CcSEcCtD
Amantadine—Constipation—Epirubicin—prostate cancer	5.1e-05	0.000257	CcSEcCtD
Amantadine—Nausea—Capecitabine—prostate cancer	5.09e-05	0.000256	CcSEcCtD
Amantadine—Dizziness—Prednisone—prostate cancer	5.05e-05	0.000254	CcSEcCtD
Amantadine—Insomnia—Doxorubicin—prostate cancer	4.99e-05	0.000251	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—prostate cancer	4.96e-05	0.000249	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—prostate cancer	4.92e-05	0.000248	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—prostate cancer	4.92e-05	0.000247	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—prostate cancer	4.91e-05	0.000247	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—prostate cancer	4.86e-05	0.000245	CcSEcCtD
Amantadine—Vomiting—Prednisone—prostate cancer	4.85e-05	0.000244	CcSEcCtD
Amantadine—Rash—Prednisone—prostate cancer	4.81e-05	0.000242	CcSEcCtD
Amantadine—Dermatitis—Prednisone—prostate cancer	4.81e-05	0.000242	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—prostate cancer	4.8e-05	0.000242	CcSEcCtD
Amantadine—Headache—Prednisone—prostate cancer	4.78e-05	0.000241	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.77e-05	0.00024	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—prostate cancer	4.76e-05	0.00024	CcSEcCtD
Amantadine—Constipation—Doxorubicin—prostate cancer	4.72e-05	0.000238	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—prostate cancer	4.72e-05	0.000237	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—prostate cancer	4.55e-05	0.000229	CcSEcCtD
Amantadine—Nausea—Prednisone—prostate cancer	4.53e-05	0.000228	CcSEcCtD
Amantadine—Hypersensitivity—Epirubicin—prostate cancer	4.4e-05	0.000221	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—prostate cancer	4.36e-05	0.00022	CcSEcCtD
Amantadine—Asthenia—Epirubicin—prostate cancer	4.28e-05	0.000215	CcSEcCtD
Amantadine—Pruritus—Epirubicin—prostate cancer	4.22e-05	0.000212	CcSEcCtD
Amantadine—Diarrhoea—Epirubicin—prostate cancer	4.08e-05	0.000205	CcSEcCtD
Amantadine—Hypersensitivity—Doxorubicin—prostate cancer	4.07e-05	0.000205	CcSEcCtD
Amantadine—Asthenia—Doxorubicin—prostate cancer	3.96e-05	0.000199	CcSEcCtD
Amantadine—Dizziness—Epirubicin—prostate cancer	3.95e-05	0.000199	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—prostate cancer	3.91e-05	0.000197	CcSEcCtD
Amantadine—Vomiting—Epirubicin—prostate cancer	3.79e-05	0.000191	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—prostate cancer	3.78e-05	0.00019	CcSEcCtD
Amantadine—Rash—Epirubicin—prostate cancer	3.76e-05	0.000189	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—prostate cancer	3.76e-05	0.000189	CcSEcCtD
Amantadine—Headache—Epirubicin—prostate cancer	3.74e-05	0.000188	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—prostate cancer	3.65e-05	0.000184	CcSEcCtD
Amantadine—Nausea—Epirubicin—prostate cancer	3.54e-05	0.000178	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—prostate cancer	3.51e-05	0.000177	CcSEcCtD
Amantadine—Rash—Doxorubicin—prostate cancer	3.48e-05	0.000175	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—prostate cancer	3.48e-05	0.000175	CcSEcCtD
Amantadine—Headache—Doxorubicin—prostate cancer	3.46e-05	0.000174	CcSEcCtD
Amantadine—Nausea—Doxorubicin—prostate cancer	3.28e-05	0.000165	CcSEcCtD
Amantadine—DRD2—GPCR ligand binding—CXCL8—prostate cancer	7.97e-06	5.71e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—INS—prostate cancer	7.93e-06	5.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—RXRA—prostate cancer	7.93e-06	5.68e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NCOA2—prostate cancer	7.91e-06	5.66e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP2E1—prostate cancer	7.9e-06	5.66e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NQO1—prostate cancer	7.81e-06	5.6e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	7.81e-06	5.6e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TCN2—prostate cancer	7.79e-06	5.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—UCP3—prostate cancer	7.79e-06	5.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTA3—prostate cancer	7.79e-06	5.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PDHA1—prostate cancer	7.79e-06	5.58e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GNG5—prostate cancer	7.78e-06	5.58e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CREBBP—prostate cancer	7.77e-06	5.57e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TH—prostate cancer	7.7e-06	5.52e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CB—prostate cancer	7.63e-06	5.46e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP3A4—prostate cancer	7.62e-06	5.46e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTGS2—prostate cancer	7.56e-06	5.41e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SLC5A5—prostate cancer	7.54e-06	5.4e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1B1—prostate cancer	7.49e-06	5.37e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HSD3B1—prostate cancer	7.43e-06	5.32e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC22A3—prostate cancer	7.43e-06	5.32e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CD—prostate cancer	7.37e-06	5.28e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP2E1—prostate cancer	7.37e-06	5.28e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NQO1—prostate cancer	7.28e-06	5.22e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GGT1—prostate cancer	7.26e-06	5.2e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	7.19e-06	5.15e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TH—prostate cancer	7.18e-06	5.14e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	7.17e-06	5.14e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NCOA1—prostate cancer	7.15e-06	5.12e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTA4—prostate cancer	7.13e-06	5.1e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TBXAS1—prostate cancer	7.13e-06	5.1e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP3A4—prostate cancer	7.1e-06	5.09e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP19A1—prostate cancer	7.04e-06	5.04e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	7.03e-06	5.04e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1B1—prostate cancer	6.98e-06	5e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NOS3—prostate cancer	6.96e-06	4.98e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTA2—prostate cancer	6.94e-06	4.97e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SULT1A1—prostate cancer	6.86e-06	4.91e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ABCG5—prostate cancer	6.86e-06	4.91e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RXRA—prostate cancer	6.8e-06	4.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFBR1—prostate cancer	6.78e-06	4.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTHLH—prostate cancer	6.78e-06	4.86e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GGT1—prostate cancer	6.76e-06	4.84e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTA1—prostate cancer	6.7e-06	4.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKR1C3—prostate cancer	6.67e-06	4.78e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NCOA1—prostate cancer	6.66e-06	4.77e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	6.64e-06	4.76e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKACB—prostate cancer	6.64e-06	4.75e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HSD3B2—prostate cancer	6.62e-06	4.74e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTO1—prostate cancer	6.62e-06	4.74e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NAT2—prostate cancer	6.62e-06	4.74e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—prostate cancer	6.59e-06	4.72e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP19A1—prostate cancer	6.57e-06	4.7e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—COMT—prostate cancer	6.55e-06	4.69e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTP1—prostate cancer	6.52e-06	4.67e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—THBS1—prostate cancer	6.47e-06	4.63e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PPP3CA—prostate cancer	6.47e-06	4.63e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CB—prostate cancer	6.42e-06	4.6e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ITPR1—prostate cancer	6.41e-06	4.59e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ANXA1—prostate cancer	6.38e-06	4.57e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTGS2—prostate cancer	6.36e-06	4.56e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PLCB2—prostate cancer	6.35e-06	4.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LRP2—prostate cancer	6.35e-06	4.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2C18—prostate cancer	6.35e-06	4.55e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RXRA—prostate cancer	6.34e-06	4.54e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—prostate cancer	6.29e-06	4.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCZ—prostate cancer	6.26e-06	4.48e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—P4HB—prostate cancer	6.23e-06	4.46e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CG—prostate cancer	6.12e-06	4.38e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—COMT—prostate cancer	6.1e-06	4.37e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	6.1e-06	4.37e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTP1—prostate cancer	6.07e-06	4.35e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—TYMS—prostate cancer	6.06e-06	4.34e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC22A1—prostate cancer	6.06e-06	4.34e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	6.06e-06	4.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PARP1—prostate cancer	6.04e-06	4.33e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR4—prostate cancer	6.04e-06	4.33e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GSTM1—prostate cancer	5.99e-06	4.29e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ITPR1—prostate cancer	5.98e-06	4.28e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CALCA—prostate cancer	5.97e-06	4.28e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SULT2A1—prostate cancer	5.9e-06	4.23e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	5.9e-06	4.23e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—LPL—prostate cancer	5.88e-06	4.21e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL12—prostate cancer	5.83e-06	4.18e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MED12—prostate cancer	5.81e-06	4.16e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GNG5—prostate cancer	5.76e-06	4.13e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP1A1—prostate cancer	5.68e-06	4.07e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—TYMS—prostate cancer	5.65e-06	4.04e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ERCC2—prostate cancer	5.63e-06	4.03e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GSTM1—prostate cancer	5.58e-06	4e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CG—prostate cancer	5.56e-06	3.98e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOA3—prostate cancer	5.55e-06	3.98e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—prostate cancer	5.55e-06	3.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP9—prostate cancer	5.49e-06	3.93e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—LPL—prostate cancer	5.48e-06	3.92e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CD—prostate cancer	5.38e-06	3.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PRKCQ—prostate cancer	5.32e-06	3.81e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NGFR—prostate cancer	5.32e-06	3.81e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—HPGDS—prostate cancer	5.3e-06	3.79e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—prostate cancer	5.29e-06	3.79e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—prostate cancer	5.29e-06	3.79e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP1A1—prostate cancer	5.29e-06	3.79e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2C19—prostate cancer	5.26e-06	3.77e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAP3K7—prostate cancer	5.26e-06	3.77e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ERCC2—prostate cancer	5.25e-06	3.76e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PPARA—prostate cancer	5.19e-06	3.72e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTT1—prostate cancer	5.14e-06	3.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ACHE—prostate cancer	5.14e-06	3.68e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2A6—prostate cancer	5.08e-06	3.64e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF10—prostate cancer	5.06e-06	3.62e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ADRB2—prostate cancer	5e-06	3.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	4.99e-06	3.57e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKR1C3—prostate cancer	4.94e-06	3.54e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—JAK2—prostate cancer	4.94e-06	3.54e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—prostate cancer	4.93e-06	3.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAP2K1—prostate cancer	4.92e-06	3.52e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PRKACB—prostate cancer	4.91e-06	3.52e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CD—prostate cancer	4.88e-06	3.5e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CAV1—prostate cancer	4.88e-06	3.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VAV3—prostate cancer	4.88e-06	3.49e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP17A1—prostate cancer	4.86e-06	3.48e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PPARA—prostate cancer	4.84e-06	3.47e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFBR2—prostate cancer	4.81e-06	3.44e-05	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	4.81e-06	3.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ITPR1—prostate cancer	4.73e-06	3.39e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CB—prostate cancer	4.69e-06	3.36e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—prostate cancer	4.65e-06	3.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOA2—prostate cancer	4.63e-06	3.32e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CAV1—prostate cancer	4.55e-06	3.26e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1R—prostate cancer	4.52e-06	3.24e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—prostate cancer	4.5e-06	3.23e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—JAK2—prostate cancer	4.48e-06	3.21e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CG—prostate cancer	4.45e-06	3.19e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SLC5A5—prostate cancer	4.42e-06	3.17e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LPL—prostate cancer	4.34e-06	3.11e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP2E1—prostate cancer	4.32e-06	3.09e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—prostate cancer	4.31e-06	3.08e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PDGFRB—prostate cancer	4.3e-06	3.08e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NQO1—prostate cancer	4.27e-06	3.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CB—prostate cancer	4.26e-06	3.05e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—INS—prostate cancer	4.21e-06	3.02e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TH—prostate cancer	4.21e-06	3.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ITGB3—prostate cancer	4.19e-06	3e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP3A4—prostate cancer	4.16e-06	2.98e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CG—prostate cancer	4.15e-06	2.97e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CREBBP—prostate cancer	4.12e-06	2.95e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1B1—prostate cancer	4.09e-06	2.93e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—prostate cancer	4.09e-06	2.93e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB3—prostate cancer	4.06e-06	2.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR2—prostate cancer	4.06e-06	2.91e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GGT1—prostate cancer	3.96e-06	2.84e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—INS—prostate cancer	3.92e-06	2.81e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—prostate cancer	3.91e-06	2.8e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CD—prostate cancer	3.91e-06	2.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—prostate cancer	3.91e-06	2.8e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NCOA1—prostate cancer	3.9e-06	2.8e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TERT—prostate cancer	3.9e-06	2.79e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP19A1—prostate cancer	3.85e-06	2.76e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CREBBP—prostate cancer	3.84e-06	2.75e-05	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—prostate cancer	3.8e-06	2.72e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HIF1A—prostate cancer	3.73e-06	2.67e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RXRA—prostate cancer	3.71e-06	2.66e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NOS3—prostate cancer	3.69e-06	2.64e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CD—prostate cancer	3.64e-06	2.61e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LEP—prostate cancer	3.64e-06	2.6e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CAV1—prostate cancer	3.6e-06	2.58e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—COMT—prostate cancer	3.58e-06	2.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KDR—prostate cancer	3.56e-06	2.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTP1—prostate cancer	3.56e-06	2.55e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ITPR1—prostate cancer	3.5e-06	2.51e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—prostate cancer	3.47e-06	2.49e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NOS3—prostate cancer	3.44e-06	2.46e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CB—prostate cancer	3.41e-06	2.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—BAD—prostate cancer	3.39e-06	2.43e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTGS2—prostate cancer	3.38e-06	2.42e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—TYMS—prostate cancer	3.31e-06	2.37e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CG—prostate cancer	3.28e-06	2.35e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APC—prostate cancer	3.28e-06	2.35e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GSTM1—prostate cancer	3.27e-06	2.34e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGF—prostate cancer	3.24e-06	2.32e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IRS1—prostate cancer	3.24e-06	2.32e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—LPL—prostate cancer	3.21e-06	2.3e-05	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—prostate cancer	3.2e-06	2.29e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CB—prostate cancer	3.18e-06	2.27e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GSK3B—prostate cancer	3.15e-06	2.26e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTGS2—prostate cancer	3.15e-06	2.25e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—INS—prostate cancer	3.11e-06	2.23e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP1A1—prostate cancer	3.1e-06	2.22e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ERCC2—prostate cancer	3.08e-06	2.2e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CREBBP—prostate cancer	3.04e-06	2.18e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1—prostate cancer	3e-06	2.15e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—EGFR—prostate cancer	2.99e-06	2.14e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—prostate cancer	2.94e-06	2.11e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAP2K1—prostate cancer	2.9e-06	2.08e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—prostate cancer	2.89e-06	2.07e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CD—prostate cancer	2.89e-06	2.07e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	2.86e-06	2.05e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SERPINE1—prostate cancer	2.85e-06	2.04e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PPARA—prostate cancer	2.84e-06	2.03e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—prostate cancer	2.82e-06	2.02e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—prostate cancer	2.81e-06	2.01e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGF2—prostate cancer	2.76e-06	1.98e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—prostate cancer	2.74e-06	1.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NOS3—prostate cancer	2.72e-06	1.95e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CAV1—prostate cancer	2.67e-06	1.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—JAK2—prostate cancer	2.65e-06	1.9e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—prostate cancer	2.62e-06	1.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	2.6e-06	1.86e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MDM2—prostate cancer	2.58e-06	1.85e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—prostate cancer	2.55e-06	1.83e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CB—prostate cancer	2.51e-06	1.8e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CG—prostate cancer	2.43e-06	1.74e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—prostate cancer	2.42e-06	1.73e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1B—prostate cancer	2.36e-06	1.69e-05	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—prostate cancer	2.33e-06	1.67e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CASP3—prostate cancer	2.31e-06	1.66e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—prostate cancer	2.31e-06	1.65e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—INS—prostate cancer	2.3e-06	1.65e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—prostate cancer	2.3e-06	1.65e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CREBBP—prostate cancer	2.25e-06	1.61e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCND1—prostate cancer	2.25e-06	1.61e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—prostate cancer	2.23e-06	1.6e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—prostate cancer	2.19e-06	1.57e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1A—prostate cancer	2.18e-06	1.56e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—prostate cancer	2.17e-06	1.56e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CD—prostate cancer	2.14e-06	1.53e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—prostate cancer	2.12e-06	1.52e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—prostate cancer	2.08e-06	1.49e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—prostate cancer	2.07e-06	1.48e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NOS3—prostate cancer	2.02e-06	1.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SRC—prostate cancer	2.02e-06	1.44e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—prostate cancer	1.96e-06	1.41e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—prostate cancer	1.94e-06	1.39e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—prostate cancer	1.94e-06	1.39e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CB—prostate cancer	1.86e-06	1.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTGS2—prostate cancer	1.84e-06	1.32e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—prostate cancer	1.81e-06	1.29e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—prostate cancer	1.8e-06	1.29e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EGFR—prostate cancer	1.77e-06	1.27e-05	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—prostate cancer	1.7e-06	1.22e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—prostate cancer	1.67e-06	1.2e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—prostate cancer	1.61e-06	1.15e-05	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—prostate cancer	1.58e-06	1.13e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—prostate cancer	1.53e-06	1.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—prostate cancer	1.53e-06	1.1e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—prostate cancer	1.48e-06	1.06e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—prostate cancer	1.36e-06	9.72e-06	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—prostate cancer	1.25e-06	8.97e-06	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—prostate cancer	1.13e-06	8.13e-06	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—prostate cancer	9.27e-07	6.64e-06	CbGpPWpGaD
